

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE DECEMBER 5, 2019 MEETING**

DUR Board Roster: State Fiscal Year 2020 (July 1, 2019- June 30, 2020)	Mar 2019	May 2019	Sep 2019	Dec 2019
Lauren Bloodworth, PharmD		✓	✓	✓
Beverly Bryant, MD	✓		✓	✓
Rhonda Dunaway, RPh	✓	✓	✓	✓
Tanya Fitts, MD	✓	✓		✓
Ray Montalvo, MD (Chair)	✓		✓	✓
Holly Moore, PharmD		✓	✓	✓
Janet Ricks, DO	✓	✓		
Dennis Smith, RPh	✓	✓	✓	✓
Cheryl Sudduth, RPh	NA	NA	✓	✓
James Taylor, PharmD	✓	✓	✓	
Alan Torrey, MD	NA	NA	✓	
Veda Vedanarayanan, MD	✓	✓	✓	
TOTAL PRESENT	10*	8*	10	8

** Total Present may not be reflected by individual members marked as present above due to members whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPh, CPM, Pharmacy Director; Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Carlos Latorre, MD, Medical Director; Sue Reno, RN, Program Integrity; Carmen Robinson, Performance Auditor, Program Integrity

University of Mississippi School of Pharmacy - MS-DUR Staff:

Eric Pittman, PharmD, MS-DUR Project Director

Conduent Staff:

Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project

Change Healthcare Staff:

Paige Clayton, PharmD, On-Site Clinical Pharmacist; Shannon Hardwick, RPh, CPC Pharmacist

Coordinated Care Organization (CCO) Staff:

Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD, Vice President Pharmacy Operations, Magnolia Health; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare

Visitors:

Brynna Clark, MPhA; Judy Clark, Consultant; Evelyn Johnson, Capital Resources; Lea Miller, Pfizer; Beau Pender, Otsuka; Brandy Sympreux, Sobi; Wendy Rockwell, Sobi; Brian Berhow, Sunovion; Doug Welch, Merck; Bruce Wallace, Azurity; Tracy Smalley, Amgen; Brent Young, GBT; Reed Branson, Capital Resources; David Large, Biohaven; Allison Balducci, BMS; Phil Hecht, Abbvie; Jon Hubanks, MSDH; Michael Peoples, Lilly

Call to Order:

Dr. Ray Montalvo, Chair, called the meeting to order at 1:05pm and welcomed everyone to the meeting.

OLD BUSINESS:

Dr. Bloodworth moved to approve the minutes from the September 2019 DUR Board Meeting, seconded by Mr. Smith and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman presented the resource utilization report for July 2019 – September 2019. Dr. Pittman pointed out trends in increased utilization of antibiotics, stimulants, influenza vaccine, and neuraminidase inhibitors; all of which are typical for this time period annually. He also pointed to a decrease in the utilization of narcotic analgesics corresponding with the implementation of opioid PA edits in August 2019.

Feedback and Discussion from Board:

Dr. Pittman updated the board on items related to topics from the September DUR Board meeting. He provided the Board with updated figures on reimbursements for influenza vaccine during the 2018-2019 flu season. Pharmacy point-of-sale (POS) reimbursements for influenza vaccine averaged \$25.7 per vaccine, while medical reimbursement averaged \$42.8 per vaccine. The Board was also presented a copy of the educational letter addressing the use of metformin as first-line therapy for diabetes drafted by Dr. Latorre. This letter will be distributed to provider member organizations.

NEW BUSINESS**Update on MS-DUR Educational Interventions:**

Dr. Pittman provided an overview of all DUR mailings that occurred September 2019 – November 2019.

Special Analysis Projects:***An Overview of Antidepressant Use in Children and Adolescents with a Focus on Tricyclic Antidepressants***

Dr. Pittman presented the DUR Board with a report on the use of antidepressants in children and adolescents, focusing on the use of tricyclic antidepressants (TCAs). Dr. Pittman highlighted the fact that the TCA medication class is currently not listed on the UPDL. Currently there are no age restrictions in the pharmacy claims processing system, via POS or SMART PA

programming. Following a robust discussion by the Board, the subsequent recommendations were presented:

- 1) DOM should implement an electronic edit for TCA therapy with minimum age limit of 25 years.
- 2) The P&T Committee should review the TCA class for addition to the UPDL as non-preferred.
- 3) Dr. Bryant, Dr. Fitts, and Dr. Vedanarayanan will work together to draft a provider education on the appropriateness of TCA therapy in children, adolescents, and young adults with MS DUR and DOM.

Dr. Bloodworth motioned to approve the recommendations, seconded by Mr. Smith, and unanimously approved by the Board.

HPV Vaccine Series Completion Rates

Dr. Pittman presented a report detailing HPV vaccine completion rates among Medicaid beneficiaries who initiated vaccination January 2017 - December 2017. Despite having higher HPV-associated cancers compared to national data, according to the Center for Disease Control and Prevention's HPV coverage data website for the percentage of adolescents ages 13-17 years who were up to date on HPV vaccination, Mississippi's adolescent up-to-date rate on HPV vaccine was only 28.8% compared to the 49% rate nationally. Following a robust discussion, the following recommendations were:

- 1) MS-DUR, along with DOM, will develop provider education emphasizing the importance of timely follow-up for beneficiaries initiating HPV vaccination series.
- 2) DUR should work with DOM to develop an initiative to encourage pharmacists to be more involved in both the initiation and completion of HPV vaccinations.
- 3) DOM will explore ways to collaborate with the Mississippi State Department of Health (MSDH) to develop strategies to increase HPV vaccination completion rates in Mississippi.

Dr. Bloodworth motioned to approve the recommendations, seconded by Dr. Fitts, and unanimously approved by the Board. Dr. Bloodworth and Dr. Fitts volunteered to work with DOM and MS-DUR to develop strategies and educational tools to increase HPV vaccine completion rates.

Buprenorphine Utilization Trends in Mississippi Medicaid

In October 2019, MSDH's Morbidity Report focused on buprenorphine prescribing practices in Mississippi. As a result of this MSDH report, MS-DUR conducted a similar analysis, specifically among Medicaid beneficiaries. Results showed that the proportional increase in buprenorphine prescribing among Medicaid beneficiaries was substantially greater than the data reported in

the MSDH Morbidity Report on buprenorphine prescribing across the entire state. Medicaid has taken multiple steps to increase beneficiary access to buprenorphine for medication assisted therapy (MAT). The Board commended DOM on initiatives implemented to increase access. Additional steps recommended to further increase beneficiary access to MAT were the following:

1) MS-DUR should work with DOM to develop education information targeting providers currently prescribing buprenorphine products to:

- inform providers of buprenorphine product utilization among Medicaid beneficiaries;
- encourage long-term (30 days supply) prescribing for buprenorphine products.

2) MS-DUR should work with DOM to develop a provider bulletin to be distributed to provider member organizations to:

- educate providers on the importance of MAT in combating opioid use disorder;
- increase awareness in not only the need but how more Medicaid providers can obtain SAMHSA* certification as an Opioid Treatment Program and authorized to prescribe buprenorphine products.

* SAMHSA = Substance Abuse and Mental Health Services Administration

3) Collaborate with MSDH to improve access to MAT across the state of Mississippi.

Dr. Bloodworth motioned to approve the recommendations, seconded by Dr. Bryant, and unanimously approved by the Board.

FDA Drug Safety Updates:

Dr. Pittman presented FDA drug safety communications for September 2019 – November 2019.

Pharmacy Program Update:

Ms. Kirby informed the DUR Board regarding the progress for the state plan amendment (SPA) for vaccination administration and reimbursement for pharmacists. Upon DOM executive director approval, the Vaccine SPA will need to be submitted to CMS for final approval. She informed the Board that pharmacy permits expire 12/31/2019 and renewals must be reported to Conduent, Medicaid's fiscal agent, in order for pharmacy claims to process on January 1, 2020 and thereafter. She stated that pharmacists Bob Lomenick and Wes Pitts' presentation of the pharmacy stakeholder group's proposal, to reimburse pharmacists for cognitive services, to Medicaid's Medical Care Advisory Committee meeting on November 1st was received favorably.

Miscellaneous:

2020 Meeting Dates/Times

March 19, 2020

June 11, 2020

September 17, 2020

December 3, 2020

**Meeting times will remain at 1 pm for the next year.*

Next Meeting Information:

Dr. Montalvo announced that the next meeting of the DUR Board will take place on March 19, 2020 at 1pm.

The meeting adjourned at 3:10 pm.

Submitted,

Eric Pittman, PharmD

Evidence-Based DUR Initiative, MS-DUR

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 117, Jackson, MS 39201

Contact Information: Office of Pharmacy:

Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: December 5, 2019 at 1PM

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

The screenshot shows the 'Mississippi Public Meeting Notices' website. At the top, there is a navigation bar with 'Search' and 'Login' links. Below this is a banner image featuring a map of Mississippi and the text 'PUBLIC MEETING NOTICES'. The main content area is titled 'ADVANCED NOTICE SEARCH' and displays 'SEARCH RESULTS'. It indicates that 1 notice was found. A table lists the search results with columns for Notice, Date, Status, Public Body, Agency, and Attachments. The single result is for the 'Drug Utilization Review Board' meeting on '12/5/2019 1:00:00 PM', published by the 'Division of Medicaid' for the 'Division of Medicaid'. An attachment is listed as 'DFA Meeting notification Dec 2019.docx' with a download icon. A 'Back' button is located at the bottom of the search results area.

Notice	Date	Status	Public Body	Agency	Attachments
Drug Utilization Review Board	12/5/2019 1:00:00 PM	Published	Division of Medicaid	Division of Medicaid	DFA Meeting notification Dec 2019.docx Download